FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 532 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Approves Osimertinib as Adjuvant Therapy for NSCLC with EGFR Exon... January 5, 2021 The long road to targeting the holy grail of the immune... November 9, 2020 Man Who Lost Wife to Breast Cancer Wants to Donate Her... June 5, 2021 A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and... September 21, 2021 Load more HOT NEWS Topical Diclofenac Gel Reduces the Incidence of Hand-Foot Syndrome in Patients... For Esophageal Cancer, Immunotherapy Likely to Play Larger Role EMA Recommends Extension of Therapeutic Indications for Tremelimumab Woman Celebrates Beating Cancer By Creating Christmas Tree Mannequins With A...
